Wall Street funds back China’s WuXi AppTec as weight-loss drug orders soar

US global asset managers, including BlackRock, have increased investments in WuXi AppTec, a Chinese pharmaceutical contractor, anticipating higher earnings from a surge in weight-loss drug manufacturing orders. HSBC's Linda Shu noted growing investor interest in China's contract development and manufacturing organisation and biotechnology sectors.